Management of Immune Checkpoint Inhibitors-related Liver Injury:Challenges in Clinical Practice
10.3969/j.issn.1008-7125.2024.06.001
- VernacularTitle:免疫检查点抑制剂相关肝损伤的管理:实践中的挑战
- Author:
Yang ZHI
1
;
Yinuo DONG
1
;
Yimin MAO
1
Author Information
1. 上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所上海市脂肪性肝病诊治研究中心(200001)
- Publication Type:Journal Article
- Keywords:
Immune Checkpoint Inhibitors;
Liver Injury;
Diagnosis;
Therapy
- From:
Chinese Journal of Gastroenterology
2024;29(6):321-324
- CountryChina
- Language:Chinese
-
Abstract:
With the increasing application of immune checkpoint inhibitors(ICIs)in tumor therapy,ICIs hepatotoxicity has emerged as an inevitable challenge.Despite the fact that relevant guidelines have specifically addressed this issue in recent years,many difficulties still exist in clinical practice.In terms of diagnosis,the lack of specific diagnostic biomarkers for ICIs hepatotoxicity and the complexity of the etiology of liver injury,concomitant medications,and the clinical phenotypes of hepatotoxicity in cancer patients can make the diagnosis of ICIs hepatotoxicity difficult.In terms of management,the optimal dose and duration of steroid therapy,the choice of different immunosuppressants as rescue therapy,and the reintroduction of ICIs therapy are yet to be supported by high-quality evidence-based medical evidence.We discussed the above-mentioned challenges faced by clinicians in this article.
